New pharmacological agents and novel cardiovascular pharmacotherapy strategies in 2024

Despite substantial advances in cardiovascular pharmacotherapy and devices in recent years, prevention and treatment of many cardiovascular diseases (CVDs) remain limited, thus reflecting the need for more effective and safer pharmacological strategies. In this review, we summarize the most relevant studies in cardiovascular pharmacotherapy in 2024, including the approval of first-in-class drugs for the treatment of resistant hypertension and pulmonary arterial hypertension, label expansions for bempedoic acid and semaglutide, and the results of major randomized clinical trials (RCTs) that have met the pre-specified primary endpoints, thereby filling some gaps in knowledge and opening new perspectives in the management of CVD, and those RCTs whose results did not confirm the proposed research hypotheses. We also include a section on drug safety, where we describe the newest data on adverse reactions and drug–drug interactions that may complicate treatment and/or reduce drug adherence with the consequent decrease in drug effectiveness. Finally, we present the most important ongoing phase 2 and phase 3 clinical trials assessing the efficacy and safety of cardiovascular drugs for the prevention and treatment of CVD.

Description

This article is being edited by Prof. Gregory Lip as a guest editor, since Stefan Agewall is the editor-in-chief of the EHJ-CVP.
A correction has been published: European Heart Journal - Cardiovascular Pharmacotherapy, Volume 11, Issue 5, August 2025, Page 485, https://doi.org/10.1093/ehjcvp/pvaf046

Keywords

Cardiovascular drugs New cardiovascular drugs Drug combinations Drug interactions and safety Cardiovascular pharmacotherapy Cardiovascular pharmacological strategies

URI

http://hdl.handle.net/10400.8/14195

Citation

Juan Tamargo, Stefan Agewall, Giuseppe Ambrosio, Claudio Borghi, Elisabetta Cerbai, Gheorghe A Dan, Heinz Drexel, Péter Ferdinandy, Erik Lerkevang Grove, Roland Klingenberg, Joao Morais, William Parker, Bianca Rocca, Patrick Sulzgruber, Anne Grete Semb, Samuel Sossalla, Juan Carlos Kaski, Dobromir Dobrev, New pharmacological agents and novel cardiovascular pharmacotherapy strategies in 2024, European Heart Journal - Cardiovascular Pharmacotherapy, Volume 11, Issue 3, May 2025, Pages 292–317, https://doi.org/10.1093/ehjcvp/pvaf012

Publisher

Oxford University Press

DOI

10.1093/ehjcvp/pvaf012

Collections

ciTechCare - Artigos
ESSLei - Artigos em revistas internacionais

CC License

cclicense-by

Altmetrics

Full item page